Pepsinogen II
Kod:14002
| Kabi | Pepsinogen II |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Kimyoluminessent immunoanaliz (CLIA)
Kutilayotgan natija topshirish vaqti
1 kun
Maxsus tayyorlik
- Do not consume alcohol for 24 hours before the blood draw.
- Avoid high-fat foods during the 24 hours before collection.
- Adults: fast for at least 12 hours; water is allowed.
- Children <1 year: withhold feeds for 30–40 minutes before collection.
- Children 1–5 years: withhold feeds for 2–3 hours before collection.
- For 30 minutes before collection, avoid strenuous exercise and minimize emotional stress.
- Refrain from smoking for 30 minutes before collection.
Qanday foydalanish
Pepsinogen II (PG II; pepsinogen C) testi H. pylori bilan bog‘liq antral gastrit, atrofik gastrit va pangastritni baholashda; peptik yara kasalligini baholashda; hamda pepsinogen I, PGI/PGII nisbati va H. pylori tekshiruvi bilan birgalikda qo‘llanganda oshqozon adenokarsinomasining yuqori xavfi bo‘lgan bemorlarni aniqlashda yordam beradi. U H. pylorini eradikatsiyadan keyingi javobni va gastrit yoki yara kasalligida shilliq qavatning bitishini kuzatishda qo‘llanilishi mumkin. Pepsinogen II ni o‘lchash gumon qilingan gastrinoma (Zollinger–Ellison sindromi) diagnostik izlanishlarini qo‘llab-quvvatlashi mumkin. Onkologiyada pepsinogen C ekspressiyasi ayrim ko‘krak bezi adenokarsinomalarida o‘sma bilan bog‘liq va prognostik marker sifatida xizmat qiladi.
Cheklovlar
Pepsinogenlar pepsinning faol bo‘lmagan oldingi shakllari bo‘lib, ularning qon zardobidagi konsentrasiyalari oshqozon shilliq qavatining funksional va struktur holatini, jumladan yallig‘lanish, atrofiya, metaplaziya va neoplaziyani aks ettiradi. Pepsinogen I oksintik (korpus) shilliq qavati tomonidan ishlab chiqariladi, pepsinogen II esa oksintik, kardial va pilorik shilliq qavat hamda Brunner bezlari tomonidan ishlab chiqariladi. H. pylori bilan bog‘liq gastrit qon aylanishidagi pepsinogen II miqdorini oshiradi. Asosan antral sohani tutuvchi infeksiya kislota ajralishi ortishi va pepsinogen sekretsiyasining ko‘tarilishi bilan kechuvchi gipergastrinemiyani keltirib chiqaradi va duodenal yara bilan bog‘liq. Bunga zid ravishda, asosan korpusni tutuvchi kasallik pepsinogen I kamayishi bilan birga oksintik atrofiyani, doimiy gipergastrinemiyani va no-oksintik shilliq qavatdan pepsinogen II ning nisbatan ko‘tarilishini keltirib chiqaradi. Natijada, PGI/PGII nisbati atrofik gastritda pasayadi va kasallik og‘irligi bilan korrelyatsiya qiladi. Pepsinogen I, pepsinogen II, gastrin-17 va H. pylori holatini bir vaqtda o‘lchash oshqozon patologiyasini umumiy baholash uchun invaziv bo‘lmagan "serologik biopsiya"ni ta’minlaydi. Atrofik gastrit vitamin B12 so‘rilishini va boshqa ozuqa moddalari o‘zlashtirilishini buzadi, bu makrositar anemiya va nevrologik asoratlarga olib kelishi mumkin; bunday bemorlarda oshqozon adenokarsinomasi xavfi oshadi. Pepsinogen II, shuningdek, gastrinomada ko‘tariladi va ayrim o‘smalar (masalan, estrogen retseptori-ijobiy, yaxshi differensiyalashgan ko‘krak bezi adenokarsinomasi) tomonidan ishlab chiqariladi; bu holatlarda uning ekspressiyasi nisbatan qulay prognoz bilan bog‘langan.
| Referens oraliq |
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ko'rsatmalar | Workup of suspected antral-predominant H. pylori gastritis with acid hypersecretion (postprandial and fasting epigastric pain, heartburn, nocturnal cough)., Assessment for possible atrophic gastritis presenting with epigastric discomfort, early satiety, or nausea., Evaluation of vitamin B12 deficiency and related complications (macrocytic anemia, neurologic deficits, diarrhea)., Evaluation of probable duodenal ulcer disease with nocturnal and fasting epigastric pain, postprandial pain 1.5–2 hours after meals, heartburn, or diarrhea., Evaluation of probable gastric ulcer disease with immediate postprandial epigastric pain, early satiety, or weight loss., Risk stratification for gastric adenocarcinoma in individuals with atrophic gastritis, high intake of smoked foods or alcohol, tobacco exposure, family history, or premalignant gastric conditions., Supportive testing in suspected gastrinoma/Zollinger–Ellison syndrome (severe epigastric or back pain, prominent reflux, refractory diarrhea)., Monitoring after H. pylori eradication therapy and during recovery of gastric mucosa in gastritis or peptic ulcer disease., Prognostic evaluation in breast adenocarcinoma to inform therapeutic planning. |
Natija og'ishlarining mumkin sabablari
Oshgan daraja
- aging
- renal dysfunction
Namunangiz talablari
| Namunangiz | Zardob |
|---|---|
| Container | Oltin/yo'lbars qopqoqli probirka (SST, gel ajratgich) |
References
Atherton JC. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol. 2006;1:63-96.
He CY, Sun LP, Gong YH, Xu Q, Dong NN, Yuan Y. Serum pepsinogen II: a neglected but useful biomarker to differentiate between diseased and normal stomachs. J Gastroenterol Hepatol. 2011 Jun;26(6):1039-46.
Vizoso F, Sánchez LM, Díez-Itza I, Merino AM, López-Otín C. Pepsinogen C is a new prognostic marker in primary breast cancer. J Clin Oncol. 1995 Jan;13(1):54-61.
Agréus L, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scandinavian Journal of Gastroenterology. 2012;47:136-147.
DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Principles and Practice of Oncology. 8th ed. Lippincott Williams & Wilkins; 2008.